Semaglutide vs Survodutide (BI 456906)
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Semaglutide and Survodutide (BI 456906) (also searched as Survodutide (BI 456906) vs Semaglutide) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Semaglutide centers on metabolic, while Survodutide (BI 456906) leans toward metabolic. On indexed research, Semaglutide is ahead (Semaglutide: 5 studies, Human clinical; Survodutide (BI 456906): 1, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Semaglutide is strongest for metabolic; Survodutide (BI 456906) for metabolic.
- •Evidence: Semaglutide Human clinical (5 studies) vs Survodutide (BI 456906) Human clinical (1).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
GLP-1 Receptor Agonist | Weight Loss & Diabetes
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Semaglutide vs Survodutide (BI 456906): side-by-side
| Metric | Semaglutide | Survodutide (BI 456906) |
|---|---|---|
| Class | Weight Loss | Weight Loss |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human clinical |
| Studies indexed | 5 | 1 |
| Research level | FDA Approved | Extensively Studied |
| Strongest effect | Metabolic & appetite | Metabolic & appetite |
| Healing & recovery | 0.0 | 0.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 5.0▲ | 5.0▲ |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 0.0 |
| Skin & aesthetics | 4.0▲ | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Semaglutide | Survodutide (BI 456906) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | — |
| Route | Subcutaneous injection (oral form also available) | — |
| Half-life | ~7 days (≈165 h) | — |
| Time to peak | 1–3 days | — |
| Duration of action | Weekly dosing | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Semaglutide?
### Semaglutide Summary Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been investigated for its role in managing type 2 diabetes and obesity. Its efficacy in promoting weight loss and improving glycemic control has garnered significant attention in recent clinical research.
Full Semaglutide profile, mechanism & studies →What is Survodutide (BI 456906)?
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Full Survodutide (BI 456906) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Metabolic | Even | Both ~5.0/5 |
| Skin | Semaglutide | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Semaglutide and Survodutide (BI 456906)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Semaglutide vs Survodutide (BI 456906): side effects
- reduced appetite22
- early satiety17
- nausea9
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Semaglutide has 5 approved studies indexed (Human clinical), and Survodutide (BI 456906) has 1 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Semaglutide or Survodutide (BI 456906) better?
It depends on your goal. Semaglutide is strongest for metabolic; Survodutide (BI 456906) for metabolic. Semaglutide has more indexed studies (5). See the goal-by-goal breakdown above.
Is Semaglutide or Survodutide (BI 456906) better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Which has more research, Semaglutide or Survodutide (BI 456906)?
Semaglutide has 5 approved studies indexed (Human clinical); Survodutide (BI 456906) has 1 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Semaglutide and Survodutide (BI 456906)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Semaglutide vs Survodutide (BI 456906)?
Semaglutide: community-reported reduced appetite, early satiety, nausea. Survodutide (BI 456906): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Semaglutide or Survodutide (BI 456906) FDA-approved?
Semaglutide is FDA-approved. Survodutide (BI 456906) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Survodutide (BI 456906) better than Semaglutide?
For metabolic, Survodutide (BI 456906) has the edge; for metabolic, Semaglutide does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.